A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

NCT07141914 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of semaglutide on heart-related outcomes and weight in adults who are overweight or obese, including those with heart failure or heart disease.

Status Completed The study has finished.

Type Observational

Participants 285,327 people

Who can join Ages 45+ · all sexes

Timeline Started 2025-08 · est. completion 2025-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07141914 ↗

Description as written by the study sponsor.

This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention). This is a retrospective cohort study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for participants in the US during January 1, 2016 - December 31, 2024.

Treatments tested

No treatment given Other

No treatment given
No treatment given Other

No treatment given

Main thing measured	Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event)
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07141914 ↗